Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Iris Biotechnologies, Inc. (OTC: IRSB).

Full DD Report for IRSB

You must become a subscriber to view this report.


Recent News from (OTC: IRSB)

Iris Biotechnologies Announces That the Japanese Patent Office Has Issued a Notice of Allowance of Its Key Patent Application - Artificial Intelligence System for Genetic Analysis
Iris Biotechnologies announces that the Japanese Patent Office has issued a notice of allowance of its Artificial Intelligence System for Genetic Analysis to be granted as a patent. This follows the issuance of a family of patents in the US, EU, Canada, Hong Kong, Australia, and New Zealand....
Source: Business Wire
Date: June, 13 2016 08:00
Iris BioTechnologies Announces Its BioWindows 3-Risk Scores System for Multi-Omic Analysis in the War Against Cancer and Other Diseases
SANTA CLARA, CA --(Marketwired - May 23, 2016) - Iris BioTechnologies Inc. (OTC PINK: IRSB) announces its BioWindows™ 3-Risk Scores System for Multi-Omic Analysis, which will be offered through its subsidiary, Iris Wellness Labs. The System performs intricate correlations, while...
Source: Marketwired
Date: May, 23 2016 16:40
Iris BioTechnologies Inc. Reports on Legal Proceedings Involving Heller Ehrman LLP
SANTA CLARA, CA --(Marketwired - November 25, 2015) - On November 20, 2015, the Ninth Circuit Court of Appeals affirmed the lower court decision denying Iris's motion to file a malpractice claim against its former legal counsel Heller Ehrman LLP. Heller Ehrman was a reputable, one-hundred-...
Source: Marketwired
Date: November, 25 2015 13:18

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-16N/A0.11N/AN/A0
2018-08-150.110.110.110.115,000
2018-08-14N/A0.07N/AN/A0
2018-08-130.100.070.100.0725,485
2018-08-10N/A0.11N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1314,00025,48554.9343Short
2018-08-08250250100.0000Short
2018-08-07200200100.0000Short
2018-07-251,9501,950100.0000Short
2018-07-101,8001,800100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on IRSB.


About Iris Biotechnologies, Inc. (OTC: IRSB)

Logo for Iris Biotechnologies, Inc. (OTC: IRSB)

Iris BioTechnologies is a life sciences company focused on personalized, precision medicine to provide you and your physicians the information to choose the best medical treatment regimen available before treatment begins. Iris enables precision healthcare. We analyze the totality of who you are, by looking at a combination of things including your DNA, family medical history, life style, and environmental exposure. Iris offers the best approach to cancer treatment through actionable integration of molecular profiling with clinical decision making, precision analysis of potential cancer recurrence and chemotherapy effectiveness, and correlating to targeted therapies and therapies in clinical trials. The Iris Nano Biochip product pipeline includes: Quick Blood Tests, CancerChip, PrenatalChip, NeuroChip Alzheimer s and Parkinson diseases , MetabolicChip Diabetes , CardioChip, and Chips for veterinary, agricultural e.g., biofuel development , environmental, and other applications. The Iris BioWindows artificial intelligence system provides big data and analysis for clinical applications, drug development, and stem cell research. For the past decade Iris BioTechnologies has been perfecting the st Century tools necessary to bring personalized, precision medicine to the clinic. Iris s state of the art Nano biochips and BioWindows medical informatics system are capable of capturing and analyzing cancer and many other diseases by integrating genomic, mRNA, microRNA, proteins or other biomarkers with medical history, clinical research, life style and environmental information. Our patented products were also developed to enable the development of companion diagnostics and new drugs. Some Iris products are designed to be used in CLIA certified laboratories without FDA approval and some other products are designed for FDA approval, enabling them to be used in any certified laboratory in the United States. Each person is biologically unique. For example, chemotherapy works on only of breast cancer patients. A patient that receives the wrong chemotherapy can result in cancer drug resistance that could preclude that patient from using the right treatment that most likely would have worked in the first place. If breast cancer or other disease strikes, who will you call to make sure that you get the right, unique diagnostic in order for your physician to offer you the right medical treatment that will work best for you We believe that in the future you may think of Iris first.

 

Contact Information

 

 

Current Management

  • Simon Chin / President, CEO, CFO
  • Grace Osborne / VP, Business Development
  • James LeBlanc / COO
  • Ralph Sinibaldi / VP, Prod. Dev.
  • Ronald Mark Gemberling / CMO
  • Paul Yaswen / CSO
  • Simon Chin /
  • Douglas Hendren, MD /
  • Grace Osborne /

Current Share Structure

  • Market Cap: $2,393,217 - 03/09/2018
  • Authorized: 20,000,000 - 05/11/2015
  • Issue and Outstanding: 21,368,011 - 11/14/2016
  • Float: 5,956,081 - 04/11/2016

 


Recent Filings from (OTC: IRSB)

Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: March, 31 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 15 2016
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 15 2016
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 15 2016
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 13 2016
All other definitive information statements
Filing Type: DEF 14CFiling Source: edgar
Filing Date: April, 29 2016
Preliminary proxy statement containing all other information
Filing Type: PRE 14CFiling Source: edgar
Filing Date: April, 05 2016
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 30 2016
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2016
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 12 2015

 

 


Daily Technical Chart for (OTC: IRSB)

Daily Technical Chart for (OTC: IRSB)


Stay tuned for daily updates and more on (OTC: IRSB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: IRSB)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in IRSB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of IRSB and does not buy, sell, or trade any shares of IRSB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/